Compass Pathways

Mental health care company

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).

Also known as...COMPASS Pathways plc
Health Politics Science
Trump Psychedelics Executive Order

Trump Psychedelics Executive Order President Trump has signed an executive order to speed up research into psychedelic drugs for mental health treatment.